ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2329

Feasibility of a Streamlined Approach for Psoriatic Arthritis Screening and Symptom Assessment

Gretchen Ball1, Hassan Hamade2, Sarah Romanelli2, Melissa Zundell2, Sangyoon Shin2, Thami Senthilkumaran2, Angela Lamb2, Saakshi Khattri3, Lourdes Perez Chada4, Joseph Merola5 and Alice Gottlieb6, 1Albert Einstein College of Medicine, Ridgefield, CT, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3Mount Sinai Medical Center, New York, NY, 4Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 5UT Southwestern Medical Center, Newton, MA, 6Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA

Meeting: ACR Convergence 2024

Keywords: , ,

Session Information

Date: Monday, November 18, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Psoriatic arthritis (PsA) is frequently undiagnosed and/or undertreated. Given the elevated risk of disability with treatment delays, we launched a quality improvement initiative to streamline PsA screening, symptom severity/impact assessment, and specialist referral to improve patient outcomes.

Methods: Following an established clinical framework, our study integrated the Psoriasis Epidemiology Screening Tool (PEST) and the Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID-12) into the electronic medical record across 26 dermatology clinics. Patients with psoriasis (PsO) underwent PsA screening via the PEST. Those scoring ≥3 or already diagnosed with PsA subsequently completed the PsAID-12, which served to inform management. Applying the validated Patient Acceptable Symptom State (PASS) cutoff, a PsAID-12 score ≤4 is considered an acceptable PsA symptom state and supported continuation of current treatment. Conversely, a score above 4 indicated an unacceptable PsA symptom state, warranting treatment modification or referral to rheumatology. Results were sent to providers in real-time for review.

Results: Over 20 months, 7,140 patients with PsO were encountered by dermatology providers, with 1,159 (16.2%) having a baseline diagnosis of PsA. In total, 2,551 PsO patients completed the PEST; 652 (25.6%) scored ≥3 and subsequently completed the PsAID-12. Of those who took the PsAID-12, 63.4% scored ≤4, reflecting effective symptom management. Of the 36.6% of patients not on target, 80 (24.4%) received rheumatology referrals.

Conclusion: These results underscore the feasibility of our framework in facilitating PsA detection and assessment, referring patients to rheumatology, and ultimately improving the quality of care.

Supporting image 1

Design of Clinical Framework.

Disclosures: G. Ball: None; H. Hamade: None; S. Romanelli: None; M. Zundell: None; S. Shin: None; T. Senthilkumaran: None; A. Lamb: Pfizer, 2, 5; S. Khattri: AbbVie, 6, Acelyrin, 5, Argenx, 1, Bristol-Myers Squibb(BMS), 5, Eli Lilly, 1, 6, Incyte, 5, Janssen, 1, 6, Leo Pharma, 5, Novartis, 1, 5, Pfizer, 5, 6, Regeneron, 1, 6, Sanofi, 1, 6, UCB, 1, 6; L. Perez Chada: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), 5; J. Merola: AbbVie, 12, Consultant and/or investigator, Amgen, 12, Consultant and/or investigator, AstraZeneca, 12, Consultant and/or investigator, Biogen, 12, Consultant and/or investigator, Boehringer Ingelheim, 12, Consultant and/or investigator, Bristol Myers Squibb, 12, Consultant and/or investigator, Dermavant, 12, Consultant and/or investigator, Eli Lilly, 12, Consultant and/or investigator, Janssen, 12, Consultant and/or investigator, MoonLake, 12, Consultant and/or investigator, Novartis, 12, Consultant and/or investigator, Pfizer, 12, Consultant and/or investigator, Sanofi-Regeneron, 12, Consultant and/or investigator, Sun Pharma, 12, Consultant and/or investigator, UCB, 12, Consultant and/or investigator; A. Gottlieb: Amgen, 1, 2, AnaptypsBio, 1, 2, Avotres Therapeutics, 1, 2, Boehringer Ingelheim, 1, 2, Bristol Myers Squibb, 1, 2, 5, Dice Therapeutics, 1, 2, Eli Lilly, 1, 2, Highlights Therapeutics, 1, 2, 5, Janssen, 1, 2, 5, Novartis, 1, 2, Sanofi, 1, 2, Teva, 1, 2, UCB, 1, 2, 5, Xbiotech, 1, 2.

To cite this abstract in AMA style:

Ball G, Hamade H, Romanelli S, Zundell M, Shin S, Senthilkumaran T, Lamb A, Khattri S, Perez Chada L, Merola J, Gottlieb A. Feasibility of a Streamlined Approach for Psoriatic Arthritis Screening and Symptom Assessment [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/feasibility-of-a-streamlined-approach-for-psoriatic-arthritis-screening-and-symptom-assessment/. Accessed .

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/feasibility-of-a-streamlined-approach-for-psoriatic-arthritis-screening-and-symptom-assessment/